Introduction
A number of reports have delineated an increased risk of all-cause and cardiovascular mortality in patients with disorders of mineral metabolism (1) (2) (3) (4) (5) . Accelerated atherosclerosis is an important cause of cardiovascular death in long-term dialysis patients (6) , and shows strong association with mineral and bone disorders (MBDs) in these patients (7) . High serum alkaline phosphatase was linearly associated with increased coronary calcification (5) and mortality (8) in dialysis patients. Dysregulation of parathyroid gland function is associated with serious skeletal abnormalities, ranging from high-turnover osteodystrophy bone disease to adynamic bone disease, that have been associated with nonskeletal consequences such as cardiovascular effects, vascular calcifications, calciphylaxis, and mortality in dialysis patients (9, 10) .
Cardiovascular disease is the leading cause of death after kidney transplantation (11) . It is therefore important to evaluate the risk factors of coronary disease before transplantation. The abnormalities of MBD are well known risk factors of mortality and coronary disease in patients on maintenance hemodialysis (4, 5, 8) . However, only few studies aimed to analyze the association between pretransplant MBDs and post-transplant outcome. We recently examined only the association of pretransplant phosphorus level and post-transplant outcome (12) . However, similar investigations for other routinely measured MBD measures, such as alkaline phosphatase, intact parathyroid hormone (iPTH), and calcium, have not yet been examined in a large cohort. Both pretransplant (13) and post-transplant (14) high serum iPTH levels were associated with inferior outcome of graft function in kidney transplant recipients. Roodnat et al. examined 407 kidney transplant recipients and found a significant, linear association between a higher pretransplant PTH level and higher risk of graft failure censored death (13) . Compared with a pretransplant serum PTH level of 100 pg/ml, pretransplant PTH levels of 300 pg/ml, 500 pg/ml, and 800 pg/ ml were associated with approximately 20%, 40%, and 80% higher risk of graft failure censored death, respectively (13) . Similarly to PTH, pretransplant (12) and post-transplant (15) serum phosphorous levels were associated with increased mortality risk in kidney transplant recipients.
Short-term delayed graft function (DGF) and acute rejection are important predictors of long-term outcome in transplant recipients. Some small studies showed that the abnormalities in markers of MBD are associated with increased risk of DGF and acute rejection (16) (17) (18) .
Thus, there is very limited knowledge on the value of biochemical markers of bone and mineral metabolism (serum alkaline phosphatase, serum iPTH, and serum calcium) and short-term outcomes such as acute rejection and DGF and long-term outcomes such as mortality and graft failure after kidney transplantation. We hypothesized that higher pretransplant serum alkaline phosphatase and serum iPTH levels are associated with poor post-transplant patient and graft survival and DGF in a large prospective cohort of incident kidney transplant recipients across the United States.
Materials and Methods

Patients
We linked data on all kidney transplant recipients listed in the Scientific Registry of Transplant Recipients (SRTR) up until June 2007 to a list of individuals with CKD by using the patients' social security numbers. These CKD patients underwent maintenance hemodialysis treatment from July 2001 to June 2006 at one of the outpatient dialysis facilities of a large, US-based dialysis organization (DaVita Inc, before its acquisition of former Gambro dialysis facilities). The study was approved by the institutional review boards of both Los Angeles Biomedical Research Institute at Harbor-UCLA and DaVita Clinical Research.
Clinical and Demographic Measures
The creation of the national DaVita dialysis patient cohort has been described previously (19) (20) (21) (22) (23) . We collected demographic data (such as age, sex, race, type of insurance, marital status, presence of diabetes, and dialysis vintage) and details of medical history data. Dialysis vintage was defined as the duration of time between the first day of dialysis treatment and the day of kidney transplantation. DGF and nonbiopsy-confirmed acute rejection data were captured from the SRTR database. In addition, medical history data (atherosclerotic heart disease, congestive heart failure, cancer, chronic obstructive pulmonary disease, cerebrovascular disease, hypertension, peripheral vascular disease, tobacco use) were captured from US Renal Data System. To minimize measurement variability, all repeated measures for each patient during any given calendar quarter (i.e., over a 13-week interval) were averaged and the summary estimate was used in all models. Timeaveraged values obtained from up to 20 calendar quarters (q1-q20) over the entire pretransplant period were used in our analyses. The first (baseline) studied quarter for each patient was the calendar quarter in which the patient's dialysis vintage was .90 days.
Laboratory Measures
Blood samples methods were described previously (19) (20) (21) (22) (23) . Most blood samples were collected predialysis with the exception of postdialysis serum urea nitrogen to calculate urea kinetics. Most laboratory values were measured monthly, including serum alkaline phosphatase, calcium, phosphorus, and albumin. Serum iPTH was measured at least quarterly using a first-generation immunoradiometric PTH assay (Nichols, San Juan Capistrano, CA) as described by Nussbaum et al. (24) . We divided patients into five a priori-defined categories based on pretransplant time-averaged serum iPTH level (,150 pg/ml, 150-300 pg/ml, 300-500 pg/ml, 500-800 pg/ml, and $800 pg/ ml values) to examine the dose-response association between pretransplant time-averaged serum iPTH categories and outcome risk. We also divided patients into four a prioridefined categories based on pretransplant time-averaged serum alkaline phosphatase level (,80 U/L, 80-,120 U/L, 120-,160 U/L, and $160 U/L values), serum time-averaged calcium level (,8.4 mg/dl, 8.4-,9.5 mg/dl, 9.5-,10.2 mg/dl, and $10.2 mg/dl values), and serum time-averaged calciumphosphorous level (,45 mg 2 /dl 2 , 45-,55 mg 2 /dl 2 , 55-,65 mg 2 /dl 2 , and $65 mg 2 /dl 2 values), respectively, similarly to our previous article (4) .
Statistical Analyses
Data were summarized using proportions (mean 6 SD). We examined P values for trends across pretransplant serum alkaline phosphatase categories. Time to event survival analyses were done to determine association of time-averaged markers of MBDs with all-cause mortality and graft failure (defined as reinitiation of dialysis treatment or retransplantation), DGF, and acute rejection. For DGF, defined as the need for any dialysis therapy in the first week after transplantation (25) , time to event was not accounted for. Survival analyses to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) of graft failure censored death or death censored graft failure used Cox proportional hazards regression. In mortality analyses, patients were followed until event (death) or censoring (graft failure or end of follow-up period), whichever happened first. In graft failure analyses, patients were followed until event (graft failure) or censoring (death or end of follow-up period), whichever occurred first. Proportional hazard assumption was tested using log(-log) against survival plots. Logistic regression models were used to estimate the odds ratio (ORs) and 95% CIs of post-transplant DGF and acute rejection.
For each regression analysis, four levels of multivariate adjustment were examined. First, an unadjusted model included pretransplant markers of MBD categories as the predictor. Second, case-mix adjusted models included the above plus age, sex, recipient race/ethnicity (African Americans and other self-categorized blacks, non-Hispanic whites, Asians, Hispanics, and others), diabetes mellitus, dialysis vintage (,6 months, 6 months to 2 years, 2-,5 years, and $5 years), primary insurance (Medicare, Medicaid, private, and others), marital status (married, single, divorced, widowed, and other or unknown), standardized mortality ratio of the dialysis clinic during entry quarter, dialysis dose as indicated by Kt/V (single pool), presence or absence of a hemodialysis catheter, and residual renal function during the entry quarter and eight comorbidities. Third, markers of malnutrition or inflammation (MMI) models included all of the above covariates plus 11 surrogates of nutritional status and inflammation measured during the last calendar quarter before transplantation including body mass index and 10 laboratory variables such as normalized protein catabolic rate as an indicator of daily protein intake, also known as the normalized protein nitrogen appearance (26) , and serum or blood concentrations of total iron-binding capacity, ferritin, calcium (except calcium analysis), phosphorous, iPTH (except iPTH analysis), bicarbonate, peripheral white blood cell count, lymphocyte percentage, and albumin. Fourth, models adjusted for case mix, MMI, and transplant data included all of the above plus eight transplant-related variables, including donor type (deceased or living), donor age, donor sex, panel reactive antibody titer (last value before transplant), number of HLA mismatches, cold ischemia time, DGF (except when DGF was a dependent variable in logistic regression models), and extended donor criteria using standard definition (donor history of hypertension and/or serum creatinine of donor .1.5 mg/dl and/or cause of death in donor is cerebrovascular event). We repeated our alkaline phosphatase analyses in patients 
Results
The original 5-year (July 2001-June 2006) national database of all DaVita patients included 164,789 adult participants. Of 65,386 DaVita patients who were identified in the SRTR database, 17,629 had undergone one or more kidney transplantations during their lifetime, but only 14,508 dialysis patients had undergone kidney transplantation for the first time. This analytic cohort was followed until death, graft failure, loss of follow-up, or survival until June 30, 2007. In the final analyses we excluded the patients who did not have serum alkaline phosphatase measurements (n=2732) or serum iPTH measurements (n=4401) or serum calcium measurements (n=2669) (Supplemental Figure 1 ). Accordingly, the final analyses were done in 11,776 patients for serum alkaline phosphatase, 10,107 patients for serum iPTH, and 11,839 patients for serum calcium (Supplemental Figure 1 ).
There were 869 deaths (7.4%) and 1320 graft failures (11.2%) irrespective of subsequent deaths in the alkaline phosphatase cohort. The median cohort time was 829 days (interquartile range, 358-1362 days). Tables 1 and 2 show the clinical, demographic, and laboratory data of the 11,776 transplanted patients across four pretransplant serum alkaline phosphatase categories. The crude all-cause mortality rate was 31.2/1000 patient-years (95% CI, 29.3-33.2).
The associations of pretransplant time-averaged serum alkaline phosphatase categories with the post-transplant risk of graft failure censored death, death censored graft failure, DGF, and acute rejection are shown in Figure 1 . A higher time-averaged serum alkaline phosphatase level showed a linear and significant (P=0.04 for serum alkaline phosphatase as continuous variable) association with higher risk of graft failure censored death in our cohort ( Figure 1A ). Similar association was found in cardiovascular mortality ( Figure 1B ). Similar, but nonsignificant, association was observed for graft loss, DGF, and acute rejection (Figure 1 , D-F). Table 3 shows the risk of posttransplant all-cause, cardiovascular, infectious graft failure censored death or death censored graft failure or DGF or acute rejection comparing different pretransplant timeaveraged serum alkaline phosphatase categories. Compared with recipients with pretransplant time-averaged serum alkaline phosphatase of 80-120 U/L, recipients with pretransplant time-averaged serum alkaline phosphatase of 120-160 and $160 U/L had 41% (HR, 1.41; 95% CI, 1.17-1.69) and 57% (HR, 1.57; 95% CI, 1.30-1.91) higher graft failure censored all-cause mortality, and recipients with pretransplant time-averaged serum alkaline phosphatase of ,80 U/L had 23% (HR, 0.77; 95% CI, 0.65-0.92) lower unadjusted graft failure censored death risk. After additional adjustment for case-mix, MMI, and transplant-related variables, recipients with pretransplant time-averaged serum alkaline phosphatase of 120-,160 and $160 U/L had 49% (HR, 1.49; 95% CI, 1.14-1.93) and 64% (HR, 1.64; 95% CI, 1.21-2.23) higher graft failure censored death risk compared with recipients with pretransplant time-averaged serum alkaline phosphatase of 80-,120 U/L ( Table 3) . Compared with recipients with pretransplant time-averaged serum alkaline phosphatase 80-,120 U/L, recipients with pretransplant time-averaged serum alkaline phosphatase of 120-,160 and $160 U/L had 111% (HR, 2.11; 95% CI, 1.26-3.52) and 100% (HR, 2.00; 95% CI, 1.10-3.65) higher graft failure censored cardiovascular mortality (Table 3 ). There was no significant association between time-averaged serum alkaline phosphatase categories and risk of death censored graft failure, DGF, or acute rejection (Table 3) . Similar results were found in patients without liver disease (Supplemental Table 1 ).
The associations of pretransplant time-averaged serum iPTH categories with the post-transplant risk of graft failure censored death, death censored graft failure, DGF, and acute rejection are shown in Figure 2 . Higher time- averaged serum iPTH level did not show (P=0.15 for iPTH as continuous variable) any association with risk of graft failure censored death in our cohort (Figure 2A) . Similar results were found in cardiovascular and infectious mortality ( Figure 2, B and C) .
In addition, the risk of graft failure, DGF, and acute rejection did not show any association with time-averaged serum iPTH level (Figure 2 , D-F). Table 4 shows the risk of post-transplant graft failure censored all-cause, cardiovascular, infectious death, death censored graft failure, DGF, (Table 4 ). Compared with recipients with pretransplant time-averaged serum iPTH level 150-300 pg/ml, recipients with pretransplant time-averaged serum iPTH of 500-800 pg/ ml iPTH had higher (HR, 2.21; 95% CI, 1.24-3.91) cardiovascular mortality risk in our multivariable adjusted model (Table 4 ). There was no association between iPTH categories and risk of graft failure, DGF, and acute rejection. The associations of pretransplant time-averaged serum calcium categories with the post-transplant risk of graft failure censored death, death censored graft failure, DGF, and acute rejection is shown in Figure 3 . Lower time-averaged serum calcium level showed a nonsignificant trend toward higher all-cause mortality risk (P=0.10 for serum calcium as continuous variable), but there was no association between serum calcium level and the risk of DGF or acute rejection. Table 5 shows the risk of post-transplant graft failure censored all-cause, cardiovascular, and infectious death or death censored graft failure, DGF, or acute rejection comparing different pretransplant time-averaged serum calcium categories. Compared with recipients with pretransplant time-averaged serum calcium of 8.4-9.5 mg/dl, recipients with pretransplant time-averaged serum calcium of 9.5-,10.2 and $10.2 mg/dl calcium had 26% (HR, 0.74; 95% CI, 0.60-0.92) and 40% (HR, 0.60; 95% CI, 0.41-0.88) lower risk of graft failure in our models adjusted for case mix, MMI, and transplant variables ( Table 5 ). There was no significant association between time-averaged serum calcium categories and risk of graft failure censored death, DGF, and acute rejection ( Table 5 ).
In addition, there was no significant association between time-averaged serum calcium-phosphorous product levels and risk of graft failure censored allcause, cardiovascular, infectious death, DGF, and acute rejection (Supplemental Table 2 and Supplemental Figure 2 ).
Discussion
In this retrospective analysis of .10,000 primary kidney transplant recipients, we describe an association between pretransplant serum alkaline phosphatase levels .120 U/L with an increased risk of graft failure censored all-cause and cardiovascular death; however, there was no association between serum iPTH and mortality. Neither pretransplant serum iPTH nor pretransplant serum alkaline phosphatase level was associated with graft loss, DGF, or acute rejection. Interestingly, pretransplant serum calcium .9.5 mg/dl was associated with decreased risk of graft loss.
The first important finding was the association of pretransplant serum alkaline phosphatase levels .120 U/L with increased risk of post-transplant graft failure censored all-cause and cardiovascular death. The association between pretransplant serum alkaline phosphatase and survival was monotonic. Supporting this observation, the same association was detected in the cohort without liver disease. Similar associations were found in our previous studies in maintenance hemodialysis patients (4, 8) . This linear association is indicative of the relation between the increasing severity of high-turnover bone disease during the dialysis period and increased mortality risk in the post-transplant period (27) (28) (29) . We did not find any association between pretransplant serum iPTH level and post-transplant outcome. In contrast, Roodnat et al. showed that serum pretransplant PTH levels were independently associated with the risk for graft failure censored for death in kidney transplant recipients (13) . However, they did not find any association between serum iPTH level and post-transplant mortality (13) . This cohort was different from our cohort in several variables: the prevalence of diabetic nephropathy was only 9.6% and the cohort was smaller (n=407).
Interestingly, pretransplant serum calcium levels .9.5 mg/dl were associated with decreased risk of graft loss. High serum calcium level during the dialysis period may be associated with usage of vitamin D and/or calcium containing phosphate binders. Vitamin D receptor is found in significant concentrations in the T lymphocyte and macrophage populations (30) . The significant role of vitamin D compounds as selective immunosuppressant is illustrated by their ability to either prevent or markedly suppress animal models of autoimmune disease (30) . The vitamin D hormone stimulates TGF-b1 and IL-4 production, which in turn may suppress inflammatory T cell activity (30) . The decreased inflammatory T cell activity may be associated with lower risk of graft loss. Unfortunately, we do not have data about vitamin D utilization; therefore, we are not able to test this speculative hypothesis. Further studies are needed to confirm this result and develop additional hypotheses to explain this observation.
Our study should be qualified for several potential limitations. Like all observational studies, ours too cannot prove causality. Post-transplant laboratory measures, type of immunosuppressive regimen, and other relevant medications (such as vitamin D and phosphate binders) were not available in the SRTR database; however, in the full model, we did adjust for a number of transplant-related variables. We did not have access to data pertaining to death after graft loss, which is another important outcome. Patients who did not have measured serum iPTH, alkaline phosphatase, and calcium levels were excluded from the analyses. The excluded patients might have been different from those included in our study, which may have biased our results. It is important to note that missing data for covariates led to exclusion of over half of the cohort for the final multivariable models. Another potential limitation is that we did not have bone-specific alkaline phosphatase data. Moreover, we cannot exclude patients with liver disease from our analysis; however we found qualitative similar results when we reanalyzed our data with patients aspartate aminotransferase #40 U/L. In addition, we did not have data about 25(OH) vitamin D, 1,25(OH)2 vitamin D, fibroblast growth factor-23, and osteocalcin levels. Moreover, we do not have data about treatment of MBD in these patients.
Strengths of this study are multilevel adjustment, which includes several important pretransplant measures, the high number of patients, and the relatively long follow-up time.
Individuals with pretransplant serum alkaline phosphatase .120 U/L have increased risk of graft failure censored all-cause and cardiovascular mortality. There was no significant association between time-averaged serum alkaline phosphatase categories and risk of death censored graft failure, DGF, or acute rejection. There was no clinically meaningful association between pretransplant serum iPTH and calcium level and post-transplant outcomes. Further clinical trials are needed to better define optimal target levels of MBD markers in waitlisted dialysis patients.
